Transenterix Inc (NYSEAMERICAN:TRXC) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 17,250,155 shares, an increase of 6.5% from the January 12th total of 16,200,995 shares. Based on an average daily volume of 2,000,529 shares, the short-interest ratio is currently 8.6 days. Approximately 11.7% of the shares of the company are short sold.
In other news, CFO Joseph P. Slattery sold 333,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total value of $975,690.00. Following the completion of the transaction, the chief financial officer now owns 440,974 shares in the company, valued at approximately $1,292,053.82. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Joseph P. Slattery sold 529,609 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $2.80, for a total transaction of $1,482,905.20. Following the completion of the transaction, the chief financial officer now owns 440,974 shares of the company’s stock, valued at approximately $1,234,727.20. The disclosure for this sale can be found here.
Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of Transenterix in the 4th quarter valued at about $109,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Transenterix in the 4th quarter valued at about $113,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Transenterix by 87.8% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 79,150 shares of the medical instruments supplier’s stock valued at $113,000 after purchasing an additional 37,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Transenterix by 94.0% in the 4th quarter. Bank of New York Mellon Corp now owns 119,584 shares of the medical instruments supplier’s stock valued at $231,000 after purchasing an additional 57,944 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Transenterix by 157.3% in the 4th quarter. BlackRock Inc. now owns 1,760,266 shares of the medical instruments supplier’s stock valued at $3,397,000 after purchasing an additional 1,076,133 shares during the last quarter.
Transenterix (TRXC) traded down $0.04 on Friday, reaching $1.33. 2,281,876 shares of the company’s stock traded hands, compared to its average volume of 2,223,832. The firm has a market cap of $282.92, a PE ratio of -2.21 and a beta of 2.20. Transenterix has a 52-week low of $0.45 and a 52-week high of $5.00.
Transenterix (NYSEAMERICAN:TRXC) last posted its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Transenterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.
TRXC has been the subject of a number of recent research reports. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the company a “buy” rating in a research note on Friday, October 20th. Stifel Nicolaus restated a “buy” rating and issued a $4.00 price objective (up previously from $3.75) on shares of Transenterix in a research note on Monday, October 30th. BTIG Research restated a “hold” rating on shares of Transenterix in a research note on Monday, December 18th. Finally, Zacks Investment Research cut shares of Transenterix from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.61.
COPYRIGHT VIOLATION NOTICE: “Transenterix Inc (TRXC) Short Interest Update” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/09/transenterix-inc-trxc-short-interest-update.html.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.